Prognostic Implications of Left Ventricular Ejection Fraction and Left Ventricular End-Diastolic Diameter on Clinical

Sijing Cheng1, Yu Deng1, Hao Huang1

  • 1State Key Laboratory of Cardiovascular Disease, Arrhythmia Center, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Beijing 100037, China.

Insights

Left ventricular end-diastolic diameter (LVEDD) better predicts mortality and appropriate shocks in implantable cardioverter defibrillator (ICD) patients than left ventricular ejection fraction (LVEF). LVEDD provides significant prognostic value for both outcomes, while LVEF is only associated with mortality.

Area of Science:

  • Cardiology
  • Medical Devices
  • Prognostic Biomarkers

Background:

  • Left ventricular ejection fraction (LVEF) is a limited predictor for implantable cardioverter defibrillator (ICD) patients.
  • Left ventricular end-diastolic diameter (LVEDD) has shown associations with mortality and arrhythmias.

Purpose of the Study:

  • To quantify the prognostic value of LVEF and LVEDD for clinical outcomes in ICD patients.
  • To compare the predictive capabilities of LVEF and LVEDD for all-cause mortality and appropriate ICD shocks.

Main Methods:

  • Retrospective analysis of ICD implantation patients.
  • Cox regression and Fine-gray competing risk regression models were used.
  • Associations between LVEF/LVEDD and all-cause mortality/appropriate shocks were analyzed.

Main Results:

  • Both LVEF and LVEDD were strongly associated with all-cause mortality.
  • LVEF did not predict appropriate shocks, but larger LVEDD was significantly associated with increased shock risk.
  • LVEDD addition improved prognostic value for mortality and shocks, whereas LVEF only improved mortality prediction.

Conclusions:

  • LVEF and LVEDD demonstrate a linear relationship with all-cause mortality in ICD patients.
  • LVEDD, but not LVEF, is linearly associated with appropriate ICD shocks.
  • LVEDD offers superior predictive value for both all-cause mortality and appropriate shocks compared to LVEF in ICD recipients.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
25
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
31
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
23
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
41